title: Internal initiation of translation efficiency in different hepatitis C genotypes isolated from interferon treated patients.
abstract: Initiation of translation of hepatitis C viral RNA occurs internally and it is mediated by a segment of about 330 nucleotides termed Internal Ribosome Entry Site (IRES) located in the 5' end region. While being the most conserved part of the genome, this region also accumulates nucleotide substitutions which are often covariant. In this study we have examined the activity and sequence variation of IRES elements belonging to genotypes 1b, 2a/2c and 3a in patients that responded or not to interferon therapy. The substitutions found in the IRES region analyzed were predicted to maintain the secondary structure of the RNA. Comparison of their efficiency to promote internal initiation of translation in bicistronic constructs supported the conclusion that for both 1b and 3a genotypes, response to interferon therapy and IRES activity are unrelated, although sequence homology was not always found among isolates from patients with different type of response. IRES activity of the studied genotypes varied about 4-fold under the conditions used in our in vivo assays depending on the cell line used for transfection. Such differences were not evidenced in vitro suggesting that the differences observed depend on trans-acting factors present in the transfected cell.
authors.affiliation: Department of Medicine, IDIBAPS, Hospital Clinic, University of Barcelona, Spain.
authors.forename: J C
authors.initials: JC
authors.lastname: Sáiz
authors.forename: S
authors.initials: S
authors.lastname: López de Quinto
authors.forename: N
authors.initials: N
authors.lastname: Ibarrola
authors.forename: F X
authors.initials: FX
authors.lastname: López-Labrador
authors.forename: J M
authors.initials: JM
authors.lastname: Sánchez-Tapias
authors.forename: J
authors.initials: J
authors.lastname: Rodés
authors.forename: E
authors.initials: E
authors.lastname: Martínez-Salas
mesh_terms: D000328:Adult; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D001483:Base Sequence; D001665:Binding Sites; D019556:COS Cells; D002460:Cell Line; D015500:Chloramphenicol O-Acetyltransferase / Q000235:genetics / Q000378:metabolism; D018076:DNA, Complementary / Q000737:chemistry / Q000235:genetics; D005260:Female; D005786:Gene Expression Regulation; D014644:Genetic Variation; D005838:Genotype; D006367:HeLa Cells; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D006526:Hepatitis C / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008156:Luciferases / Q000235:genetics / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D010442:Peptide Chain Initiation, Translational; D014176:Protein Biosynthesis / Q000235:genetics*; D012367:RNA, Viral / Q000235:genetics / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012270:Ribosomes / Q000378:metabolism; D016415:Sequence Alignment; D017422:Sequence Analysis, DNA; D012689:Sequence Homology, Nucleic Acid; D014407:Tumor Cells, Cultured
chemical_list: D000998:Antiviral Agents; D018076:DNA, Complementary; D012367:RNA, Viral; D011993:Recombinant Fusion Proteins; D007372:Interferons; D008156:Luciferases; D015500:Chloramphenicol O-Acetyltransferase